Charles Schwab Portfolio holdings
Charles Schwab Corporation, founded in 1971 by Charles R. Schwab and headquartered in Westlake, Texas, is a leading financial services firm that revolutionized retail investing by offering low-cost brokerage services. Initially disrupting the industry with discount commissions, it has grown into a powerhouse providing a wide array of services, including trading platforms, robo-advisors, retirement accounts, and banking products, managing hundreds of billions in client assets. Known for its user-friendly technology and customer-centric approach, Schwab caters to individual investors, financial advisors, and institutions, notably expanding through its 2020 acquisition of TD Ameritrade. With a mission to democratize investing, Charles Schwab remains a dominant force in the shift toward accessible, self-directed wealth management.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
UnitedHealth
UNH
|
+$3.69B |
| 2 |
Abbott
ABT
|
+$3.65B |
| 3 |
Qualcomm
QCOM
|
+$3.54B |
| 4 |
Procter & Gamble
PG
|
+$3.42B |
| 5 |
Accenture
ACN
|
+$3.28B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Cisco
CSCO
|
+$2.86B |
| 2 |
AbbVie
ABBV
|
+$2.71B |
| 3 |
Valero Energy
VLO
|
+$1.86B |
| 4 |
Lockheed Martin
LMT
|
+$916M |
| 5 |
Halliburton
HAL
|
+$856M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 23.91% |
| 2 | Financials | 10.68% |
| 3 | Healthcare | 10.19% |
| 4 | Industrials | 8.63% |
| 5 | Consumer Discretionary | 8.4% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1851
Teladoc Health
TDOC
$1.61B
| $16.6M | ﹤0.01% |
3,037,974
+491,352
| +19% | +$2.76M |
|
1852
Pacira BioSciences
PCRX
$1.04B
| $16.5M | ﹤0.01% |
732,042
+55,690
| +8% | +$1.24M |
|
1853
Compass Minerals
CMP
$1.25B
| $16.4M | ﹤0.01% |
704,438
-95,926
| -12% | -$2.26M |
|
1854
Immunovant
IMVT
$8.23B
| $16.4M | ﹤0.01% |
660,438
+17,464
| +3% | +$452K |
|
|
GTM
1855
ZoomInfo Technologies
GTM
$908M
| $16.4M | ﹤0.01% |
2,739,166
+331,117
| +14% | +$2.43M |
|
1856
Collegium Pharmaceutical
COLL
$1.15B
| $16.4M | ﹤0.01% |
495,027
+47,745
| +11% | +$2.02M |
|
|
LGN
1857
Legence Corp
LGN
$5.2B
| $16.4M | ﹤0.01% |
289,692
-11,661
| -4% | -$588K |
|
1858
Algonquin Power & Utilities
AQN
$4.63B
| $16.3M | ﹤0.01% |
2,675,980
-68,987
| -3% | -$447K |
|
|
PRA
1859
DELISTED
ProAssurance
PRA
| $16.2M | ﹤0.01% |
656,614
-11,931
| -2% | -$291K |
|
1860
Lindsay Corp
LNN
$1.17B
| $16.2M | ﹤0.01% |
136,316
+4,680
| +4% | +$594K |
|
1861
Agios Pharmaceuticals
AGIO
$2.2B
| $16.1M | ﹤0.01% |
477,032
-5,590
| -1% | -$158K |
|
|
SOBO
1862
South Bow Corp
SOBO
$7.79B
| $16.1M | ﹤0.01% |
484,380
+43,176
| +10% | +$1.31M |
|
1863
Disc Medicine
IRON
$2.85B
| $16.1M | ﹤0.01% |
251,195
+4,156
| +2% | +$288K |
|
1864
OR Royalties Inc
OR
$5.54B
| $16M | ﹤0.01% |
422,319
-13,078
| -3% | -$537K |
|
1865
Enact Holdings
ACT
$6.57B
| $16M | ﹤0.01% |
392,099
+10,405
| +3% | +$425K |
|
1866
National Grid
NGG
$81.6B
| $16M | ﹤0.01% |
188,674
+25,770
| +16% | +$2.22M |
|
1867
Employers Holdings
EIG
$906M
| $15.9M | ﹤0.01% |
387,697
+2,305
| +0.6% | +$97.5K |
|
1868
Adaptive Biotechnologies
ADPT
$3.61B
| $15.9M | ﹤0.01% |
1,145,682
-27,853
| -2% | -$444K |
|
|
NPKI
1869
NPK International
NPKI
$1.19B
| $15.9M | ﹤0.01% |
1,095,601
-68,174
| -6% | -$946K |
|
1870
Ubiquiti
UI
$32.7B
| $15.8M | ﹤0.01% |
20,041
+493
| +3% | +$335K |
|
1871
Astrana Health
ASTH
$1.89B
| $15.8M | ﹤0.01% |
644,171
+95,019
| +17% | +$2.25M |
|
|
ORKA
1872
Oruka Therapeutics
ORKA
$5.44B
| $15.8M | ﹤0.01% |
321,949
-7,547
| -2% | -$262K |
|
1873
Baytex Energy
BTE
$2.94B
| $15.8M | ﹤0.01% |
3,539,927
+133,165
| +4% | +$491K |
|
|
TWO
1874
Two Harbors Investment
TWO
$1.27B
| $15.7M | ﹤0.01% |
1,378,605
-25,748
| -2% | -$288K |
|
1875
Safety Insurance
SAFT
$1.51B
| $15.7M | ﹤0.01% |
216,001
-5,050
| -2% | -$384K |
|
Similar funds
Charles Schwab's Q1 2026 Portfolio in Review
As of Q1 2026, Charles Schwab held 3,535 positions worth $654B, up 1.7% from $644B the previous quarter. Its ten largest holdings account for 22% of the portfolio.
Charles Schwab deployed $21.4B of net new capital in Q1 2026, opening 79 new positions and adding to 1,903 existing holdings. Its largest new stake was JPMorgan Income ETF: 8,679,689 shares worth $400M.
By sector, the portfolio is most concentrated in Technology at 24% of assets, down from 25% a quarter earlier, followed by Financials and Healthcare.
On the sell side, the largest reduction was Cisco, an estimated $2.86B trimmed.
- Charles Schwab's largest Q1 2026 buy was JPMorgan Income ETF: 8,679,689 shares worth $400M.
- Charles Schwab added most to UnitedHealth in Q1 2026, an estimated $3.69B increase.
- Charles Schwab's biggest Q1 2026 reduction was Cisco, cutting an estimated $2.86B.
- Charles Schwab fully exited Comerica in Q1 2026, selling an estimated $412M.
- Charles Schwab's ten largest holdings make up 22% of its $654B portfolio in Q1 2026.
- Charles Schwab opened 79 new positions and closed 80 in Q1 2026.
- Charles Schwab's portfolio value rose 1.7% quarter-over-quarter to $654B.
Based on Charles Schwab's 13F filing for Q1 2026, filed 15 May 2026.